<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299298</url>
  </required_header>
  <id_info>
    <org_study_id>MIPO3700710</org_study_id>
    <secondary_id>2010-021948-18</secondary_id>
    <nct_id>NCT01299298</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen Administered Subcutaneously to Japanese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kastle Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kastle Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is being conducted to evaluate 3 increasing subcutaneous (SC) doses (50,&#xD;
      mg, 100 mg or 200mg) of mipomersen in Japanese healthy volunteers. Eligible subjects will&#xD;
      receive a single study injection of either mipomersen or placebo. Subjects will be enrolled&#xD;
      into 1 of 3 treatment cohorts (Cohorts A, B, and C) in a dose-escalation design.&#xD;
      Dose-escalation will proceed only if there is an acceptable safety profile from the previous&#xD;
      dosing level.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Baseline up to Day 36 Post-Treatment</time_frame>
    <description>plasma PK parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximal concentration (Tmax)</measure>
    <time_frame>Baseline up to Day 36 Post-Treatment</time_frame>
    <description>plasma PK parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>Baseline up to Day 36 Post-Treatment</time_frame>
    <description>plasma PK parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Day 36 Post-Treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>mipomersen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) SC single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mipomersen</intervention_name>
    <description>50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug</description>
    <arm_group_label>mipomersen</arm_group_label>
    <other_name>ISIS 301012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First generation Japanese (born in Japan of Japanese parents and Japanese&#xD;
             grandparents), lived no more than 5 years outside of Japan, with no significant change&#xD;
             in lifestyle or habits, including diet, while living outside of Japan.&#xD;
&#xD;
          -  Surgically sterile, abstinent or subject or partner compliant with acceptable&#xD;
             contraceptive during and 24 weeks after the last study drug dose&#xD;
&#xD;
          -  Body weight &gt;50 kg and body mass index between 18 and 30 kg/m2 inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant cardiovascular, pulmonary, hepatic, renal, haematologic,&#xD;
             gastrointestinal, endocrine, immunologic, dermatologic, neurologic, infectious, or&#xD;
             psychiatric disease&#xD;
&#xD;
          -  Clinically significant abnormal findings on the physical examination, ECG, blood&#xD;
             pressure, heart rate, medical history, or clinical laboratory results at Screening or&#xD;
             before dosing&#xD;
&#xD;
          -  Positive test for human immunodeficiency virus (HIV), hepatitis B or C.&#xD;
&#xD;
          -  High sensitivity C-reactive protein (hsCRP) &gt;5 mg/L&#xD;
&#xD;
          -  History of or current malignancy (with the exception of basal or squamous cell&#xD;
             carcinoma of the skin if adequately treated and no recurrence for &gt; 1 year)&#xD;
&#xD;
          -  Evidence of acute or ongoing chronic inflammatory condition or infection&#xD;
&#xD;
          -  History of rash, impetigo, or drug allergies&#xD;
&#xD;
          -  Alcohol and/or drug abuse&#xD;
&#xD;
          -  Smoking more than 10 cigarettes per day&#xD;
&#xD;
          -  Planned dental work up to and including Day 8 procedures&#xD;
&#xD;
          -  Treatment with another investigational drug, biological agent, or device within 4&#xD;
             weeks of Screening or 5 half-lives of the study agent, whichever is longer&#xD;
&#xD;
          -  Use of prescribed medications within 4 weeks or over-the counter medications&#xD;
             (including dietary supplements and herbal remedies) within 14 days before the first&#xD;
             study drug dose, or use of any concomitant medications (prescribed or over the&#xD;
             counter) through Day 8 of the study without Investigator and Sponsor approval.&#xD;
             Vaccinations are not allowed beginning 3 weeks prior to the first dose of study drug&#xD;
             until completion of the safety follow-up period&#xD;
&#xD;
          -  Previous exposure to oligonucleotide-based drug therapy&#xD;
&#xD;
          -  Donated 50 to 499 mL of blood within 30 days prior to consent, or &gt;499 mL within 60&#xD;
             days&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>FOCUS Clinical Drug Development GmbH</name>
      <address>
        <city>Stresemannallee 6, Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <last_update_submitted>August 1, 2016</last_update_submitted>
  <last_update_submitted_qc>August 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mipomersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

